3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Testicular Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Death
1
Colonic Neoplasms
1
Interventions
Sunitinib
26
Everolimus
20
Bevacizumab
19
aldesleukin
18
Sorafenib
16
Nivolumab
16
Interleukin-2
14
pembrolizumab
13
Peripheral Blood Stem Cell Transplantation
13
fludarabine phosphate
12
Radiotherapy
12
Interferon-alpha
12
Cyclophosphamide
12
Radiosurgery
11
Filgrastim
11
Blood Specimen Collection
11
Ipilimumab
10
Gemcitabine
10
Axitinib
9
Surveys and Questionnaires
7
Gene Expression Profiling
7
Cryosurgery
7
temsirolimus
6
pazopanib
6
Surgical Procedures, Operative
6
durvalumab
5
cabozantinib
5
atezolizumab
5
Mycophenolic Acid
5
Immunohistochemistry
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Kidney Neoplasms
×
erythromycin propionate-N-acetylcysteinate
×
Clear all
NCT02966509
2018-10-31
EPAC
Stanford University
Phase NA
Completed
213 enrolled
20 charts